ArticleCell proliferation2020
High-efficient generation of VCAM-1
Article in Cell proliferation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Stem cell-based tactics in the remodeling and treatment of intestinal diseases.Stem cell research & therapy · 2026Review
- Reparative effects of VCAM-1 high-performance MSC-derived exosomes on aged diabetic cardiomyocyte injury: a focus on ferroptosis suppression.Apoptosis : an international journal on programmed cell death · 2026Article
- Mesenchymal Stromal Cells: Bridging the Gaps in Hematologic Disease Therapy.Stem cell reviews and reports · 2026Review
- Role of Interleukin-10 Overexpressing Mesenchymal Stem Cells in Promoting Bone Marrow Functional Recovery in Aplastic Anemia Mice.Stem cells international · 2026Article
- Application of stem cells in the precise diagnosis and treatment of liver diseases.World journal of gastroenterology · 2025Review
- Decoding the multifaceted cellular and transcriptomic variations of natural killer cells generated from patients with Parkinson's disease.Scientific reports · 2025Article
- Quality by design strategy of human mesenchymal stem/stromal cell drug products for the treatment of knee osteoarthritis.World journal of stem cells · 2025Review
- Exosomes derived from hUC-MSCs exhibit ameliorative efficacy upon previous cesarean scar defect via orchestrating β-TrCP/CHK1 axis.Scientific reports · 2025Article
- VCAM-1Neurochemical research · 2024Article
- Article
- Unveiling heterogeneity in MSCs: exploring marker-based strategies for defining MSC subpopulations.Journal of translational medicine · 2024Review
- Characterization of the biological and transcriptomic landscapes of bone marrow-derived mesenchymal stem cells in patients with multiple myeloma.Cancer cell international · 2024Article
- Improved therapeutic consistency and efficacy of CD317Stem cell research & therapy · 2024Article
- Uncovering the cellular and omics characteristics of natural killer cells in the bone marrow microenvironment of patients with acute myeloid leukemia.Cancer cell international · 2024Article
- Mesenchymal stem cells (MSCs) from the mouse bone marrow show differential expression of interferon regulatory factors IRF-1 and IRF-2.Molecular biology reports · 2024Article
- Mesenchymal stem cells derived from adipose tissue and umbilical cord reveal comparable efficacy upon radiation-induced colorectal fibrosis in rats.American journal of cancer research · 2024Article
- VCAM-1Neurochemical research · 2023Article
- Development of Hetero-Cell Type Spheroids Via Core-Shell Strategy for Enhanced Wound Healing Effect of Human Adipose-Derived Stem Cells.Tissue engineering and regenerative medicine · 2023Article
- Human UC-MSC-derived exosomes facilitate ovarian renovation in rats with chemotherapy-induced premature ovarian insufficiency.Frontiers in endocrinology · 2023Review
- Characterization of the biological and transcriptomic signatures of natural killer cells derived from cord blood and peripheral blood.American journal of cancer research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveLongitudinal studies have indicated VCAM-1 MATERIALS AND
methodsWe primarily took advantage of a cytokine-based programming strategy for large-scale VCAM-1
resultsIII-MSCs with high-proportioned VCAM-1 expression were obtained by combining IL-1β, IL-4 with IFN-γ, which exhibited comparable immunophenotype with untreated hUC-MSCs (NT-MSCs) but revealed multidimensional superiorities both at the cellular and molecular levels. Simultaneously, systemic infusion of III-MSCs could significantly ameliorate clinicopathological features and finally help facilitate haematopoietic reconstruction and immunoregulation in AA mice.
conclusionsWe have established a high-efficient procedure for large-scale generation of III-MSCs with preferable signatures and efficacy upon aplastic anaemia in mice. Our findings suggested that III-MSCs were advantageous sources with multifaceted characteristics for regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.